-
Je něco špatně v tomto záznamu ?
Screening of genomic imbalances in glioblastoma multiforme using high-resolution comparative genomic hybridization
Vranová V, Necesalová E, Kuglík P, Cejpek P, Pesáková M, Budínská E, Relichová J, Veselská R.
Jazyk angličtina Země Řecko
NLK
Free Medical Journals
od 2006 do Před 1 rokem
- MeSH
- chromozomální aberace MeSH
- cytogenetické vyšetření MeSH
- dospělí MeSH
- financování organizované MeSH
- genom lidský MeSH
- glioblastom diagnóza genetika MeSH
- hybridizace in situ fluorescenční MeSH
- hybridizace nukleových kyselin MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory mozku diagnóza genetika MeSH
- sekvenční analýza DNA MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
Comparative genomic hybridization (CGH) is a molecular cytogenetic technique that allows the genome-wide analysis of DNA sequence copy number differences. We applied conventional CGH and the recently developed high-resolution CGH (HR-CGH) to tumour samples from 18 patients with glioblastoma multiforme (GBM) in order to compare the sensitivity of CGH and HR-CGH in the screening of chromosomal abnormalities. The abnormalities were studied in topologically different central and peripheral tumour parts. A total of 78 different changes were observed using CGH (0-16 per tumour, median 3.5) and 154 using HR-CGH (0-21 per tumour, median 6). Using HR-CGH, losses were more frequent than gains. The representation of the most prominent changes revealed by both methods was similar and was comprised of the amplification of 7q12 and 12q13-q15, the gain of 7, 3q and 19, and the loss of 10, 9p, and 13q. However, HR-CGH detected certain other abnormalities (the loss of 6, 14q, 15q and 18q, and the gain of 19), which were rarely revealed by CGH. Using HR-CGH, the numbers and types of chromosomal changes detected in the central and peripheral parts of GBM were almost the same. The loss of chromosomes 10 and 9p and the gain of chromosomes 7 and 19 were the most frequent chromosomal alterations in both tumour parts. Our results from the GBM analysis show that HR-CGH technology can reveal new, recurrent genetic alterations involving the genes known to participate in tumorigenesis and in the progression of several human malignancies, thus allowing for a more accurate genetic characterization of these tumours.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc09003776
- 003
- CZ-PrNML
- 005
- 20111210153300.0
- 008
- 091124s2007 gr e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Vallová, Vladimíra. $7 mub2011669456
- 245 10
- $a Screening of genomic imbalances in glioblastoma multiforme using high-resolution comparative genomic hybridization / $c Vranová V, Necesalová E, Kuglík P, Cejpek P, Pesáková M, Budínská E, Relichová J, Veselská R.
- 314 __
- $a Department of Genetics and Molecular Biology, Institute of Experimental Biology, Faculty of Science, Masaryk University, and Department of Medical Genetics, University Hospital, Brno, Czech Republic
- 520 9_
- $a Comparative genomic hybridization (CGH) is a molecular cytogenetic technique that allows the genome-wide analysis of DNA sequence copy number differences. We applied conventional CGH and the recently developed high-resolution CGH (HR-CGH) to tumour samples from 18 patients with glioblastoma multiforme (GBM) in order to compare the sensitivity of CGH and HR-CGH in the screening of chromosomal abnormalities. The abnormalities were studied in topologically different central and peripheral tumour parts. A total of 78 different changes were observed using CGH (0-16 per tumour, median 3.5) and 154 using HR-CGH (0-21 per tumour, median 6). Using HR-CGH, losses were more frequent than gains. The representation of the most prominent changes revealed by both methods was similar and was comprised of the amplification of 7q12 and 12q13-q15, the gain of 7, 3q and 19, and the loss of 10, 9p, and 13q. However, HR-CGH detected certain other abnormalities (the loss of 6, 14q, 15q and 18q, and the gain of 19), which were rarely revealed by CGH. Using HR-CGH, the numbers and types of chromosomal changes detected in the central and peripheral parts of GBM were almost the same. The loss of chromosomes 10 and 9p and the gain of chromosomes 7 and 19 were the most frequent chromosomal alterations in both tumour parts. Our results from the GBM analysis show that HR-CGH technology can reveal new, recurrent genetic alterations involving the genes known to participate in tumorigenesis and in the progression of several human malignancies, thus allowing for a more accurate genetic characterization of these tumours.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a nádory mozku $x diagnóza $x genetika $7 D001932
- 650 _2
- $a chromozomální aberace $7 D002869
- 650 _2
- $a cytogenetické vyšetření $7 D020732
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a genom lidský $7 D015894
- 650 _2
- $a glioblastom $x diagnóza $x genetika $7 D005909
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hybridizace in situ fluorescenční $7 D017404
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a hybridizace nukleových kyselin $7 D009693
- 650 _2
- $a sekvenční analýza DNA $7 D017422
- 700 1_
- $a Nečesalová, Eva. $7 _AN040753
- 700 1_
- $a Kuglík, Petr, $d 1957- $7 ola2003204793
- 700 1_
- $a Cejpek, Pavel $7 xx0073420
- 700 1_
- $a Pešáková, Martina $7 xx0103063
- 700 1_
- $a Budinská, Eva $7 xx0142844
- 700 1_
- $a Relichová, Jiřina, $d 1945- $7 nlk19990073774
- 700 1_
- $a Veselská, Renata, $d 1968- $7 mzk2003196540
- 773 0_
- $w MED00179060 $t Oncology reports $g Roč. 17, č. 2 (2007), s. 457-464 $x 1021-335X
- 910 __
- $y 8 $a ABA008 $b x
- 990 __
- $b ABA008 $a 20091123115031
- 991 __
- $a 20091207084746 $b ABA008
- 999 __
- $a ok $b bmc $g 697583 $s 559960
- BAS __
- $a 3
- BMC __
- $a 2007 $b 17 $c 2 $d 457-464 $m Oncology reports $x MED00179060
- LZP __
- $a 2009-B3/dkme